Abstract:Photodynamic therapy (PDT) is a photochemistry based treatment modality that involves the generation of cytotoxic species through the interactions of a photosensitizer molecule with light irradiation of an appropriate wavelength. PDT is an approved therapeutic modality for several cancers globally and in several cases has proved to be effective where traditional treatments have failed. The key parameters that determine PDT efficacy are 1. the photosensitizer (nature of the molecules, selectivity, and macroscop… Show more
“…The separation of tumors into small and large groups illuminates the distinct sizeâdependent therapeutic efficacy of PDT in this model, which can be attributed to a number of causes. Light scattering properties of tissue limit the effective depth penetration of 690 nm light to several millimeters . Spherical tumors with a volume of 65 mm 3 (the largest in this study at the time of PDT treatment) have a diameter of 5 mm, suggesting that the entire tumor may not receive the full light dose.…”
Longitudinal monitoring of tumor size in vivo can provide important biological information about disease progression and treatment efficacy that is not captured by other modes of quantification. Ultrasound enables high-throughput evaluation of orthotopic mouse models via fast acquisition of three-dimensional tumor images and calculation of volume with a reasonable degree of accuracy. Herein, we compare orthotopic pancreatic tumor volume measurements determined by ultrasound with volume measured by calipers and tumor weight, and found strong correlations between the three modalities over a large range of tumor sizes, suggesting ultrasound can accurately quantify tumor volumes in this model. Furthermore, we demonstrate the unique ability of longitudinal treatment monitoring to reveal a tumor size-dependent response to Benzoporphyrin Derivative photodynamic therapy (BPD-PDT) and irinotecan. Small tumors (5-35 mm ) were found to respond well to a single round of PDT, while large tumors (35-65 mm ) showed no response to the same treatment. These results highlight the role that tumor size can play in preclinical interpretation of treatment response and more generally suggest that careful evaluation of subtle biological features such as this must be carefully considered in order to grant a more comprehensive understanding of disease biology in vivo.
“…The separation of tumors into small and large groups illuminates the distinct sizeâdependent therapeutic efficacy of PDT in this model, which can be attributed to a number of causes. Light scattering properties of tissue limit the effective depth penetration of 690 nm light to several millimeters . Spherical tumors with a volume of 65 mm 3 (the largest in this study at the time of PDT treatment) have a diameter of 5 mm, suggesting that the entire tumor may not receive the full light dose.…”
Longitudinal monitoring of tumor size in vivo can provide important biological information about disease progression and treatment efficacy that is not captured by other modes of quantification. Ultrasound enables high-throughput evaluation of orthotopic mouse models via fast acquisition of three-dimensional tumor images and calculation of volume with a reasonable degree of accuracy. Herein, we compare orthotopic pancreatic tumor volume measurements determined by ultrasound with volume measured by calipers and tumor weight, and found strong correlations between the three modalities over a large range of tumor sizes, suggesting ultrasound can accurately quantify tumor volumes in this model. Furthermore, we demonstrate the unique ability of longitudinal treatment monitoring to reveal a tumor size-dependent response to Benzoporphyrin Derivative photodynamic therapy (BPD-PDT) and irinotecan. Small tumors (5-35 mm ) were found to respond well to a single round of PDT, while large tumors (35-65 mm ) showed no response to the same treatment. These results highlight the role that tumor size can play in preclinical interpretation of treatment response and more generally suggest that careful evaluation of subtle biological features such as this must be carefully considered in order to grant a more comprehensive understanding of disease biology in vivo.
“…To this end, we specifically investigated and reported the efficacy of IR700-YY146 PIT in melanomas. [43] Delivering light to large or disseminated tumors has been largely limited by attenuation in potency as the light penetrates into deep tissues, resulting in reduced efficacy of PDT in tumor tissues. Moreover, we found that production of surplus ROS (including singlet oxygen), reduced glucose metabolism and suppression of CD146 expression synergistically contribute to the superior therapeutic effect of IR700-YY146 PIT in small melanomas.…”
Section: Discussionmentioning
confidence: 99%
“…The strong antitumor effect of IR700-YY146 PIT herein raises the possibility that IR700-YY146 PIT is a promising therapeutic option for early-stage cutaneous melanomas, provided that the tumor is CD146-positive. [43] However, future studies are needed to shed light on the impact of repeated IR700-YY146 PIT and dosage of IR700-YY146 (or laser) on the therapeutic outcome in advanced large melanomas. Overwhelming ROS production may play a key role in mediating the treatment outcome, since Fujimoto et al previously reported that ROS scavengers obviated the therapeutic efficacy of IR700-mAb conjugates.…”
For melanoma resistant to molecularly targeted therapy and immunotherapy, new treatment strategies are urgently needed. A molecularly targeted theranostic pair may thus be of importance, where the diagnostic probe facilitates patient stratification and the therapeutic companion treats the selected cases. For this purpose, flow cytometry is used to assess the CD146 level in melanoma cells. Based on YY146, a CD146âspecific monoclonal antibody, an imaging probe
89
ZrâDfâYY146 is synthesized and its diagnostic performance is evaluated by positron emission tomography (PET) imaging. Furthermore, a photoimmunotherapy (PIT) agent IR700âYY146 is developed and the therapeutic effect of IR700âYY146 PIT is assessed comprehensively. CD146 is highly expressed in A375 and SKâMELâ5 cells.
89
ZrâDfâYY146 PET readily detects CD146âpositive A375 melanomas. Tumor accumulation of
89
ZrâDfâYY146 peaks at 72 h with an uptake value of 26.48 ± 3.28%ID g
â1
, whereas the highest uptake of the nonspecific
89
ZrâDfâIgG is 4.80 ± 1.75%ID g
â1
. More importantly, IR700âYY146 PIT effectively inhibits the growth of A375 tumors, owing to production of reactive oxygen species, decreased glucose metabolism, and reduced expression of CD146. To conclude,
89
ZrâDfâYY146 and IR700âYY146 are a promising theranostic pair with the former revealing CD146 expression in melanoma as a PET probe and the latter specifically treating CD146âpositive melanoma as an effective PIT agent.
“…The dye has a strong absorption peak close to 700 nm allowing light to penetrate deep into the tissue [70,71]. Moreover, IR700 does not develop off-target effects since they cannot be taken up by cells and cannot exert cytotoxicity even after illumination [72,73]. …”
Considerable research efforts have been dedicated to understanding ovarian and breast cancer mechanisms, but there has been little progress translating the research into effective clinical applications. Hence, personalized/precision medicine has emerged because of its potential to improve the accuracy of tumor targeting and minimize toxicity to normal tissue. Targeted therapy in both breast and ovarian cancer has focused on antibodies, antibody drug conjugates (ADCs), and very recently the introduction of human antibody fusion proteins. Small molecule inhibitors and monoclonal antibodies (mAbs) are used in conjunction with chemotherapeutic drugs as a form of treatment but problems arise from a board expression of the target antigen in healthy tissues. Also, insufficient tumor penetration due to tight binding affinity and macromolecular size of mAbs compromise the efficacy of these ADCs. A more targeted approach is thus needed, and ADCs were designed to meet this need. However, in ADCs the method of conjugation of drug to antibody is >1, altering the structure of the drug which leads to off-target effects. Random conjugation also causes the drug to affect the pharmokinetics and biodistribution of the antibody and may cause nonspecific binding and internalization. Recombinant therapeutic proteins achieve controlled conjugation reactions and combine cytotoxicity and targeting in one molecule. They can also be engineered to extend half-life, stability and mechanism of action, and offer novel delivery routes. SNAP-tag fusion proteins are an example of a theranostic recombinant protein as they provide a unique antibody format to conjugate a variety of benzyl guanine modified labels, e.g. fluorophores and photosensitizers in a 1:1 stoichiometry. On the one hand, SNAP tag fusions can be used to optically image tumors when conjugated to a fluorophore, and on the other hand the recombinant proteins can induce necrosis/apoptosis in the tumor when conjugated to a photosensitizer upon exposure to a changeable wavelength of light. The dual nature of SNAP-tag fusions as both a diagnostic and therapeutic tool reinforces its significant role in cancer treatment in an era of precision medicine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citationsâcitations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.